Clinical Therapeutics

Editorial comment
pp. 789-789(1)
Author: Krosnick A.

Clinical review of once-daily beclomethasone dipropionate for seasonal allergic rhinitis
pp. 790-796(7)
Author: Chervinsky P.

The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension
pp. 797-810(14)
Authors: Oparil S.; Dyke S.; Harris F.; Kief J.; James D.; Hester A.; Fitzsimmons S.

Comparison of the efficacy and tolerability of once-daily ceftibuten and twice-daily cefprozil in the treatment of children with acute otitis media
pp. 811-820(10)
Authors: Blumer J.L.; Forti W.P.; Summerhouse T.L.

Dorzolamide versus pilocarpine as adjunctive therapies to timolol: a comparison of patient preference and impact on daily life
pp. 821-832(12)
Authors: Laibovitz R.; Boyle J.; Snyder E.; Strohmaier K.; Adamsons I.

Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube
pp. 833-842(10)
Authors: Chun A.H.C.; Shi H.H.; Achari R.; Dennis S.; Cavanaugh J.H.

Piroxicam fast-dissolving dosage form in the treatment of patients with acute low back pain
pp. 843-852(10)
Authors: Englert R.; Fontanesi G.; Muller P.; Ott H.; Rehn L.; Silva H.

The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study
pp. 853-863(11)
Authors: Heinonen T.M.; Stein E.; Weiss S.R.; McKenney J.M.; Davidson M.; Shurzinske L.; Black D.M.

Usefulness of low-dose, once-daily quinapril as monotherapy for patients with hypertension
pp. 864-873(10)
Authors: Olvera S.; Alcocer L.; Novoa G.

Pharmaceutical economics & health policy - Editorial comment
pp. 876-876(1)
Author: Sclar D.A.

The relative community burden of otitis media and varicella
pp. 877-886(10)
Authors: Yawn B.P.; Yawn R.A.; Lydick E.

A review of health-related quality-of-life measures used in end-stage renal disease
pp. 887-938(52)
Authors: Edgell E.T.; Coons S.J.; Carter W.B.; Kallich J.D.; Mapes D.; Damush T.M.; Hays R.D.

A retrospective assessment of cost avoidance associated with the use of nedocromil sodium metered-dose inhaler in the treatment of patients with asthma
pp. 939-952(14)
Authors: Thomas P.; Ross R.N.; Farrar J.R.

A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx⁽R)) versus intravenous phenytoin (Dilantin⁽R)) in hospital emergency departments
pp. 953-966(14)
Authors: Marchetti A.; Magar R.; Fischer J.; Sloan E.; Fischer P.

Editorial comment
pp. 968-968(1)
Author: McGhan W.F.

The future of pharmacoeconomics: bridging science and practice
pp. 969-978(10)
Author: Drummond M.F.

Evaluating quality-of-life and health status instruments: development of scientific review criteria
pp. 979-992(14)
Authors: Lohr K.N.; Aaronson N.K.; Alonso J.; Audrey Burnam M.; Patrick D.L.; Perrin E.B.; Roberts J.S.

A cost density analysis of benign prostatic hyperplasia
pp. 993-1004(12)
Authors: Lanes S.F.; Sulsky S.; Walker A.M.; Isen J.; Grier C.E.; Edelman Lewis B.; Dreyer N.A.